In the evolving field of orthopedic materials, few innovations have garnered as much attention as the i-FACTOR peptide enhanced bone graft. As someone who follows advancements in biotechnology and material science, I have found the development of this specific i-FACTOR bone graft to be a fascinating look at how synthetic biology can influence structural recovery. This article explores the mechanics, clinical context, and technological evolution of this unique Peptide Enhanced Bone Graft.
The Core Tech Sep 24, 2024 — i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one nology: P-15 Peptide
At the heart of the product is the P-15 Peptide. To understand its significance, one must look at its biological mimicry. P-15 is a synthetic 15-amino acid sequence that replicates the cell-binding domain of human type-1 collagen. By serving as a powerful cell attachment factor, it creates an environment that encourages cellular interaction.
The i-FACTOR is the first spinal bone graft powered by P-15 Osteogenic Cell Binding Peptide, representing a departure from traditional graft materials. Because i-FACTOR is a composite bone substitu i-FACTOR bone graft is based on synthetic small peptide (P-15) technology developed by Cerapedics to support bone growth through cell attachment and activation. te material consisting of this peptide adsorbed onto an organic bone mineral, it provides a stable scaffold that encourages natural biological processes.
Rigorous Clinical Validation
One of the most impressive aspects of this technology is the clinical data supporting its use. The i-FACTOR met all 4 FDA-mandated noninferiority success criteria, demonstrating both safety and efficacy in long-term follow-up studies. Specifically, researchers have noted that the i-FACTOR reduced costs within the first year by 1.4% to 2.1%, highl PearlMatrix | Cerapedics Corporate ighting that this technology is cost-effective compared to autograft in ACDF surgery.
It is important to note that this is a Class III FDA approved bone graft, which signifies the high level of regulatory scrutiny applied to such devices. Because summary of safety and effectiveness data (sSED) it is a specialized material, it should only be used by doctors who are trained in using it and who understand the specific surgical requirements for its application.
Expansion and Evolution: From i-FACTOR to PearlMatrix
The product landscape has evolved significantly. While the original i-FACTOR Peptide Enhanced Bone Graft remains a staple, the technology has expanded. Notably, i-FACTOR is now approved for single-level anterior cervical discectomy fusion (ACDF), and recent updates have indicated that i-FACTOR can now be used with most commercial interbody cages.
Furthermore, the Cost-Effectiveness of Peptide Enhanced Bone Graft i-Factor brand has gro by JS Harrop · 2026 · Cited by 3 — P-15L, an FDA-designated breakthrough device, is a composite bone graft with P-15, a 15-amino acid polypeptide that promotes cellular adhesion, proliferation, wn with the introduction of PearlMatrix P-15 Peptide Enhanced Bone Graft. In fact, i-FACTOR®+Matrix is now PearlMatrix P-15 Peptide Enhanced Bone Graft, which is marketed as the first bone growth accelerator proven to accelerate lumbar fusion. This transition reflects the continued refinement of the P-15 technology, with PearlMatrix™ P-15 Peptide Enha P-15 nced Bone Graft building upon the same foundational science that made the original product a success.
Key Considerations for Use
The application of this technology is strictly defined. It is indicated for use in skeletally mature patients for specific reconstruction tasks. The i-FACTOR® Peptide Enhanced Bone Graft is designed to be used in conjunction with standard surgical protocols, and its integration into clinical practice is supported by its status as an FDA-designated breakthrough device (specifically regarding P-15L variants).
Whether discussing the original Cerapedics' i-FACTOR P-15 Peptide Enhanced Bone Graft or the newer iterations, the underlying goal remains the same: to provide a consistent, synthetic, and highly engineered environment that supports structural integrity. The shift toward these advanced materials suggests a future where synthetic peptides play a much larger role in how we approach the reconstruction of degenerated tissues, m Use of i-Factor Peptide Enhanced Bone Graft During oving away from more invasive, traditional alternatives.
*Disclaimer: This article is for informational purposes only and describes technological advancements in orthopedic materials. It does not constitute medical advice, diagnosis, or treatment recommendations.*